|
業務類別
|
-- |
|
業務概覽
|
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months. |
| 公司地址
| 320 Lorimer Street, Unit 2, Port Melbourne, VIC, AUS, 3207 |
| 電話號碼
| +61 386814050 |
| 傳真號碼
| +61 386814099 |
| 公司網頁
| https://www.polynovo.com |
| 員工數量
| 301 |
| Dr. Robyn Elliott, PhD |
Director, Acting Chief Executive and Managing Director |
-- |
25/08/2025 |
|
|
| Mr. David Williams |
Chairman of the Board |
25/08/2025 |
| Dr. Robyn Elliott, PhD |
Director, Acting Chief Executive and Managing Director |
25/08/2025 |
| Ms. Christine Emmanuel-Donnelly |
Director |
25/08/2025 |
| Mr. Leon Hoare |
Director |
25/08/2025 |
| Mr. Bruce Rathie, M.B.A. |
Director |
25/08/2025 |
| Mr. Andrew Lumsden, C.A. |
Director |
25/08/2025 |
|
|
|
|
